title: Delivery of recombinant gene product to canine brain with the use of microencapsulation.
abstract: An alternative approach to somatic gene therapy is to deliver a therapeutic protein by implanting "universal" recombinant cells that are immunologically protected from graft rejection with alginate microcapsules. This strategy has proved successful in reversing pathologic conditions in several rodent models of human disease (dwarfism, lysosomal storage disease, hemophilia, cancer). In particular, neurologic disease and behavioral deficit in the mouse model of a neurodegenerative disease (mucopolysaccharidosis [MPS] VII) were significantly improved through the intraventricular implantation of the recombinant encapsulated cells. Here we report the feasibility of delivering recombinant gene products to the central nervous systems (CNSs) of dogs, first using human growth hormone as a marker for delivery in normal dogs and then using alpha-iduronidase as a therapeutic product for delivery in the MPS I dog that is genetically deficient in this lysosomal enzyme. Madin-Darby canine kidney cells were genetically modified to express either human growth hormone or canine alpha-iduronidase, then enclosed in alginate-poly-l-lysine-alginate microcapsules of about 500 microm in diameter. The encapsulated cells were implanted into the brain under steoreotaxic guidance. The brains were monitored with computed tomographic scans before and after surgery and examined biochemically and histologically. Delivery of gene products, as measured in the plasma and cerebrospinal fluid sampled periodically through 21 days or in various regions of the brain after death showed that the delivery of both gene products was extremely low but detectable. However, we noted extensive inflammatory reactions, both at the sites of implantation and in the immediate vicinity of the implanted microcapsules. Hence for this technology to be applicable to the CNSs of larger animals and human beings, a more accurate and less invasive neurosurgical procedure, more biocompatible microcapsule-recombinant cell combinations, and higher output of recombinant products must be developed.
authors.affiliation: Department of Biology, McMaster University, Hamilton, Ontario, Canada.
authors.forename: Susan C
authors.initials: SC
authors.lastname: Barsoum
authors.forename: William
authors.initials: W
authors.lastname: Milgram
authors.forename: William
authors.initials: W
authors.lastname: Mackay
authors.forename: Craig
authors.initials: C
authors.lastname: Coblentz
authors.forename: Kathleen H
authors.initials: KH
authors.lastname: Delaney
authors.forename: Jacek M
authors.initials: JM
authors.lastname: Kwiecien
authors.forename: Stephen A
authors.initials: SA
authors.lastname: Kruth
authors.forename: Patricia L
authors.initials: PL
authors.lastname: Chang
mesh_terms: D000818:Animals; D001921:Brain / Q000378:metabolism*; D002460:Cell Line; D004285:Dogs; D016503:Drug Delivery Systems; D015316:Genetic Therapy / Q000379:methods*; D013006:Growth Hormone / Q000008:administration & dosage; D007068:Iduronidase / Q000008:administration & dosage* / Q000276:immunology; D008059:Mucopolysaccharidosis I / Q000628:therapy*; D011994:Recombinant Proteins / Q000008:administration & dosage*; D019076:Transgenes
chemical_list: D011994:Recombinant Proteins; D013006:Growth Hormone; D007068:Iduronidase